Investor Presentaiton
34
•
INO-5401 Results: Promising 12-Month Overall Survival Data and 6-
Month Progression-Free Survival Data; OS18 Data in 4Q2020
Overall survival at 12 months (OS12) to be presented at ASCO
2020 Annual Meeting
•
MGMT Promoter Unmethylated OS12 of 84.4%
•
MGMT Promoter Methylated OS12 of 85%
•
•
Compares favorably with historical value of 65%
Previously reported PFS6 at SITC 2019
.
.
MGMT Promoter Unmethylated PFS6 of 75%
MGMT Promoter Methylated PFS6 of 80%
Compares favorably with historical value of 40-60%
IFN- SFU/10€ PBMC
Immunology Output to Date
All subjects
10000-
1000-
100-
10-
1
WT1
PSMA hTERT INO-5401
n=11
Baseline
Subjects with sample to week 24
10000-
1000-
100-
10-
Week 9
WT1
PSMA
n=8
hTERT INO-5401
Week 21
.
Majority of patients tested had a T cell immune response to
one or more tumor-associated antigens encoded by INO-5401
• Combination of INO-5401 + INO-9012 with cemiplimab, with
radiation and temozolomide, is promising
.
Overall survival results (OS18) will be presented 4Q 2020
Several patients have experienced pseudo-progression, with progression by RANO criteria and
radiographic evidence of progression on MRI, without evidence of tumor on repeat biopsy
INOVIO
POWERING DNA MEDICINES
Stupp et al. N Eng J Med 2005; Hegi et al. N Eng J Med 2005; Stupp et al. N Eng J Med 2009View entire presentation